India to Turkmenistan: Amikacin Export Trade Route

To import finished pharmaceutical formulations containing Amikacin into Turkmenistan, manufacturers must adhere to the registration process outlined by the State Registration Center for Medicinal Products under the Ministry of Health and Medical Industry of Turkmenistan. The registration dossier is submitted in the national format, not the Common Technical Document (CTD) or electronic CTD (eCTD).

The registration procedure involves several key steps:

2. State Fee Payment: Applicants are required to pay the prescribed state fees associated with the registration process.

3. Examination of Documents: The submitted dossier undergoes a thorough review to ensure compliance with national standards.

4. Laboratory Analysis: Product samples are tested to verify quality and conformity to specifications.

5. Inclusion in the State Register: Upon successful evaluation, the product is listed in the State Register of Medicinal Products authorized for manufacture or importation into Turkmenistan.

6. Issuance of Registration Certificate: A registration certificate is granted, authorizing the import and distribution of the product within Turkmenistan.

The entire registration process typically spans 3-4 months from the date of application submission, excluding the time required for fee payments. (deltaswiss.eu)

While inspections of manufacturing facilities are not routinely conducted during registration, the regulatory authority reserves the right to perform inspections if deemed necessary. (cratia.ua)

Indian manufacturers exporting Amikacin formulations to Turkmenistan must possess a valid Good Manufacturing Practice (GMP) certificate, which should be notarized and included in the registration dossier. (pharmacopoeia.ru) This certification ensures that the manufacturing processes meet the quality standards required by Turkmenistan's regulatory authorities.

Specific information regarding Indian facilities currently approved by Turkmenistan's National Drug Regulatory Authority (DRA) is not publicly disclosed. Additionally, there are no publicly available records of recent inspections or regulatory actions taken by the National DRA against Indian pharmaceutical companies exporting to Turkmenistan.

As of March 2026, there have been no publicly reported regulatory changes, new guidelines, mutual recognition agreements, or policy shifts affecting Indian pharmaceutical exports to Turkmenistan within the past 18 months. The existing procedures and requirements for the registration and importation of pharmaceutical products, including Amikacin formulations, remain consistent with the established framework.

As of 2025, Turkmenistan's pharmaceutical imports were valued at approximately $30 million. While specific data on Amikacin formulations is limited, the country's reliance on imports suggests a significant portion of these pharmaceuticals are sourced externally. The demand for Amikacin is primarily driven by the prevalence of bacterial infections, particularly in hospital settings, and the country's commitment to improving healthcare infrastructure. The aging population and increased healthcare spending further contribute to the demand for effective antibiotics like Amikacin.

Turkmenistan maintains a 0% MFN import duty rate for pharmaceutical products classified under HS code 30049099, which includes finished formulations containing Amikacin. This exemption underscores the government's policy to facilitate the importation of essential medicines. There are no specific Free Trade Agreements (FTAs) between India and Turkmenistan that affect pharmaceutical tariffs, and no anti-dumping duties have been reported on these imports.

India is a key supplier of pharmaceutical formulations to Turkmenistan, including Amikacin products. Other major supplying countries include Germany, which exported pharmaceutical products worth approximately $689,100 to Turkmenistan in 2000. While specific data on India's share of Turkmenistan's total Amikacin imports is not available, India's competitive pricing and established pharmaceutical manufacturing capabilities position it favorably against competitors like China and European Union manufacturers.

India is a global leader in the production of generic pharmaceuticals, supplying approximately 20% of the world's generic medicines by volume as of 2024. The country has established a robust manufacturing infrastructure, producing over 60,000 generic drugs across 60 therapeutic categories. This extensive capacity enables the efficient production of finished dosage forms containing Amikacin, such as injections, at competitive costs. India's pharmaceutical industry is supported by a large number of WHO-GMP and FDA-approved facilities, ensuring adherence to international quality standards. In 2024, India surpassed the United States in the number of FDA-registered generic manufacturing sites, with 752 FDA-approved, 2,050 WHO-GMP-certified, and 286 EDQM-approved plants. This regulatory compliance, combined with cost-effective production capabilities, positions India as a preferred source for Amikacin formulations globally.

When comparing Amikacin formulation exports, India offers a compelling balance of cost and quality. While specific per-unit pricing data for Amikacin formulations is limited, India's overall pharmaceutical exports are known for their affordability. In 2024, India's pharmaceutical exports grew by 9%, nearly twice the global average, indicating strong demand driven by cost-effectiveness. China, another major exporter, often competes on price but may face challenges in meeting stringent regulatory standards required by markets like Turkmenistan. The European Union (EU) offers high-quality branded generics but at a higher cost, which may not be as economically viable for buyers in Turkmenistan. India's pharmaceutical industry is characterized by a strong regulatory framework, with numerous FDA and WHO-GMP-certified facilities, ensuring consistent quality and compliance with international standards. This combination of affordability, quality, and regulatory acceptance makes India a reliable source for Amikacin formulations.

India's pharmaceutical manufacturing sector demonstrates significant capacity and reliability in supplying Amikacin formulations. The country has a well-established infrastructure for producing finished dosage forms, including injectables, supported by advanced packaging and cold chain logistics to maintain product integrity. In 2024, India's pharmaceutical exports reached $25.3 billion, reflecting the industry's robust production capabilities. The regulatory compliance track record of Indian manufacturers is strong, with a high number of FDA and WHO-GMP-certified facilities ensuring adherence to international quality standards. While specific data on recent supply disruptions for Amikacin formulations is not readily available, India's overall pharmaceutical export growth and capacity suggest a reliable supply chain. Additionally, the Indian pharmaceutical industry is projected to grow at a CAGR of 10.5% from 2024 to 2030, indicating ongoing expansion and investment in manufacturing capabilities.

For Turkmenistan buyers sourcing Amikacin formulations from India, the following strategic recommendations are advised:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Amikacin formulations.

• Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts and storage capabilities. Indian suppliers may offer flexibility, but clear communication is essential to establish mutually beneficial terms.

• Payment Terms: Familiarize yourself with common payment terms in India-Turkmenistan pharmaceutical trade, such as Letters of Credit (LC) or advance payments, to facilitate smooth transactions.

• Supplier Qualification Process: Implement a thorough qualification process, including audits of manufacturing facilities, verification of regulatory certifications (e.g., FDA, WHO-GMP), and assessment of quality control systems to ensure compliance with international standards.

• Regulatory Compliance: Ensure that the selected suppliers have a strong track record of regulatory compliance and can provide the necessary documentation to meet Turkmenistan's import requirements.

By adhering to these recommendations, buyers can establish a reliable and cost-effective supply chain for Amikacin formulations from India.

1. Verify Manufacturer's Registration with Turkmenistan's Ministry of Health and Medical Industry: Confirm that the Indian supplier is registered and authorized to export pharmaceutical products to Turkmenistan.

2. Assess Validity of Good Manufacturing Practice (GMP) Certification: Ensure the manufacturer holds a current GMP certificate issued by a recognized authority, such as India's Central Drugs Standard Control Organization (CDSCO).

3. Review Drug Master File (DMF): Obtain and evaluate the DMF to understand the manufacturing process, controls, and quality standards of the Amikacin formulation.

4. Evaluate Quality Management Systems: Confirm the manufacturer has robust quality systems, including standard operating procedures, quality control measures, and compliance with international standards.

5. Check Regulatory Approvals in Other Markets: Determine if the manufacturer has approvals from stringent regulatory authorities (e.g., US FDA, EMA) for the same or similar products, indicating adherence to high-quality standards.

6. Request Stability Data: Ensure the manufacturer provides stability data compliant with International Council for Harmonisation (ICH) guidelines, demonstrating the product's shelf life under various conditions.

7. Confirm Product Registration in Turkmenistan: Verify that the specific Amikacin formulation is registered with Turkmenistan's regulatory authorities, as unregistered products cannot be legally imported or sold.

8. Conduct On-Site Audit: Plan and perform an on-site audit of the manufacturing facility to assess compliance with GMP and other relevant standards.

9. Review Supply Chain and Logistics Capabilities: Assess the manufacturer's ability to deliver products consistently and on time, including their logistics, warehousing, and distribution practices.

10. Establish Pharmacovigilance Procedures: Ensure the manufacturer has systems in place for monitoring and reporting adverse drug reactions, in line with Turkmenistan's developing pharmacovigilance framework.

1. Certificate of Analysis (CoA): Provides detailed results of laboratory testing for a specific batch, confirming the product meets predefined specifications.

2. Certificate of Origin (CoO): Certifies the country where the product was manufactured, essential for customs clearance and verifying the product's authenticity.

3. Good Manufacturing Practice (GMP) Certificate: Issued by a competent authority, this certificate confirms the manufacturer complies with GMP standards, ensuring product quality and safety.

4. Stability Data: Includes studies demonstrating the product's shelf life and stability under various environmental conditions, in accordance with ICH guidelines.

5. Batch Manufacturing Records: Detailed documentation of the production process for each batch, ensuring traceability and consistency in manufacturing.

6. Drug Master File (DMF): Comprehensive document detailing the manufacturing process, controls, and quality standards of the product.

7. Free Sale Certificate from CDSCO: Indicates that the product is approved for sale in India and is freely sold in the Indian market, suggesting compliance with local regulations.

8. Insurance Certificates: Proof of liability insurance covering potential product defects or issues, providing financial protection in case of adverse events.

9. Product Registration Certificate in Turkmenistan: Confirms that the product is registered and approved for sale in Turkmenistan, ensuring legal compliance.

10. Packaging and Labeling Samples: Examples of the product's packaging and labeling to verify compliance with Turkmenistan's regulatory requirements, including language and information standards.

1. Recent Regulatory Actions: Be cautious of manufacturers with recent warning letters or sanctions from regulatory bodies such as the US FDA or WHO, indicating compliance issues.

2. Suspension of WHO-GMP Certification: A suspension suggests significant deviations from GMP standards, raising concerns about product quality and safety.

3. Unusually Low Pricing: Prices significantly below market rates may indicate substandard materials, compromised manufacturing processes, or other quality issues.

4. Lack of Stability Data: Inability to provide comprehensive stability data raises questions about the product's shelf life and efficacy over time.

5. Limited Export History: Manufacturers without a track record of exporting to regulated markets may lack experience in meeting stringent quality and regulatory standards.

6. Resistance to Facility Audits: Hesitation or refusal to allow on-site inspections suggests potential compliance issues or deficiencies in manufacturing practices.

7. Inconsistent Documentation: Discrepancies or incomplete information in provided documents can indicate poor record-keeping or attempts to conceal issues.

8. Negative Industry Reputation: Reports of previous quality issues, recalls, or adverse events associated with the manufacturer should prompt further investigation.

By adhering to this structured approach, Turkmenistan companies can effectively qualify Indian suppliers of Amikacin formulations, ensuring compliance with regulatory standards and safeguarding public health.